Galsky, M. D., Valderrama, B. P., Maruzzo, M., Pous, A. F., Ciuleanu, T., Chatzkel, J. A., Koie, T., Hoimes, C. J., Puente, J., Zakharia, Y., Rosenbaum, E., Boehm, K., Loriot, Y., Bedke, J., Wirtz, H., Mihm, M., Huang, Q., Rogiers, J., Moreno, B. H., Lista, A. G. D. L. (2026). Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.lba630